Aktiesnakken — November 2009
-
screening af patienter starter i q4 2009
-
uhh den skal måske købes derefter long term
-
avanz.... nyt SCIT prodcut lanceret..... hvad dt kan ved jeg ikke lige præcis som ikke biotek-nørd
-
avanz is fully reimbursed....
-
will be registrered over the coming years
-
andre highlights.
-
"Pre-pen" re-introduced i usa.
-
alk er exclusiv disributør.
-
opkøb af thermo-care...... meget lille overlap mellem kunder.... thermocare vs alk.
-
ingen effekt på 2009 forventninger
-
Om regulatory environment i europa. Fra oct 2009 ingen reimbursement af non-registrered products
-
i holland
-
der var nogle detaljer om tab af salg jeg ikke lige fik fat i.. noget med 10-15%
-
omkring invesment programme.... stort set afsluttet.
-
ser fortsat "satisfactory growth
prospects in alk" -
det er opsummering af 2009
-
in the long term vi står til at profitere fra the change in regularoty environment
-
så er der Q&A
-
Michael Novod, Handelsbanken
-
flavour on the dutch situation? hvornår vil andre produkter tage over fra det faldende salg pga. den fjernede reimbursement
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind